Federal contract award
75N91018F00059
EBOLA VIRUS AND OTHER INFECTIOUS DISEASES
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 561210 — Facilities Support Services |
| PSC | M1HA — OPERATION OF GOVERNMENT-OWNED CONTRACTOR-OPERATED (GOCO) R&D FACILITIES |
| Parent award / vehicle | HHSN261201500003I |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $56.4M |
| Current contract value | $56.4M |
| Potential contract value / ceiling | $56.4M |
| Start date | Sep 30, 2018 |
| Current end date | Sep 21, 2028 |
| Potential end date | Sep 21, 2028 |
| Latest award activity | Sep 2, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 21 of 21 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 2, 2025 | P00020 | $-8.4M | EOI: IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI. |
| Apr 24, 2025 | P00019 | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI. |
| Sep 23, 2024 | P00018 | $-86.6K | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Aug 2, 2024 | P00017 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| May 3, 2024 | P00016 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Feb 13, 2024 | P00015 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Oct 16, 2023 | P00014 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Sep 21, 2023 | P00013 | $19.4M | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Sep 1, 2023 | P00012 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Aug 1, 2023 | P00011 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Dec 14, 2022 | P00010 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Aug 9, 2022 | P00009 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Mar 18, 2022 | P00008 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Dec 22, 2021 | P00007 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Sep 24, 2021 | P00006 | $2.1M | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Apr 13, 2021 | P00005 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Dec 18, 2020 | P00004 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Oct 27, 2020 | P00003 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Apr 24, 2020 | P00002 | $0 | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Sep 27, 2019 | P00001 | $13.0M | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
| Sep 28, 2018 | 0 | $30.3M | EBOLA VIRUS AND OTHER INFECTIOUS DISEASES |
Estimated positioning window
Sep 21, 2027 – Mar 21, 2028
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2028-09-21 (690 days from calculation)
- +25 points
- 25 historical awards in this buyer and category group
- +15 points
- 21 recorded award transactions
- +10 points
- Latest award action: 2025-09-02
- +0 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.